NPR, November 28, 2016. “The bad news is that so much of patient input is involving patients who are working with or who are recruited by drug companies,” cautions NCHR’s Diana Zuckerman.
Read More »Our Interviews, Blogs & OpEds
Congress Shouldn’t Pass FDA Reform Bills Without Addressing Patient Safety and Drug Prices
The Health Care Blog, November 23, 2016. Find out why NCHR president is worried about the 21st Century Cures Act and cautions strongly against its hasty passage in lame-duck session.
Read More »Does the FDA Have a High Enough Standard for Drug Approvals?
STAT News, September 28, 2016. Is the Food and Drug Administration’s approval process broken? At a HUBweek panel hosted by STAT, experts explored that question in light of the FDA’s decision last week to approve a controversial drug for Duchenne muscular dystrophy, a rare disease.
Read More »Pro and Con: Experience Well-Suits Her to Deliver Affordable Care to All
Southcoast Today and others, September 23-25, 2016. Published in newspapers across the country, this syndicated column discusses the changes needed to improve the Affordable Care Act.
Read More »21st Century Cures Act: Yes or No? No: Act’s Promise of Quick Cures Is a Brew of Ultra-Hype Mixed With Snake Oil
Chicago Tribune, July 21, 2016. If you or a loved one has a deadly disease, whether it is cancer or a rare disease, you deserve treatments that work. If experimental drugs are your only hope, they should be free as part of a study that you can choose to participate in.
Read More »